Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Metastatic Renal Cell Carcinoma
Title   A Randomized, Double-blind, Placebo-controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-CABO) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Summary   This main purpose of this study is to evaluate CB-839 in combination with Cabozantinib versus placebo with Cabozantinib for patients with advanced or metastatic renal cell carcinoma who have failed at least one treatment.
Description   Patients will randomly be placed in one of two arms. One group will receive CB-839 taken twice daily by mouth with a cabozantinib injection daily, while the other group will receive a placebo taken twice daily with a cabozantinib injection daily.
IRB Number   18005
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: Patients must be 18 years or older, documented diagnosis of renal cell carcinoma with a clear cell component and must have had 1-2 prior lines of treatment for advanced or metastatic renal cell carcinoma. Patients that have had gastric surgery or other conditions that may interfere with the absorption of the study drug are not eligible.
Status   Open
Start Date   03/27/2018
Principal Name   Mary O’Keeffe, MD
Contact Name   Tara Simon, RN
Email   Tara.Simon@nyulangone.org
Fax   516-663-1871
Current Trial Type   Interventional
Phone   516-663-1822
Alternate Phone   516-663-3115